Affymetrix and XRGenomics LTD to Collaborate on Development of a New Generation of Diagnostic Tests for Age-Related Diseases
05 November 2015 - 10:30PM
Business Wire
Affymetrix, Inc. (NASDAQ: AFFX) and XRGenomics LTD, a UK based
biotechnology company, announced today that they will collaborate
on research and development of a new generation of diagnostic tests
for age-related diseases. Over 50% of healthcare costs are spent on
those aged 65 and older and according to the G8 Summit 2013,
age-related diseases could bankrupt Western medicine by 2050. New
solutions are required to deliver efficient and effective care.
XRGenomics has utilized Affymetrix technology to develop novel
gene expression-based signatures that enable translational research
and biomarker test development activities in areas such as
dementia, Alzheimer’s, and other age-related diseases.
“Our unique approach to building diagnostics for complex
diseases that become prevalent with age requires a high-throughput
global transcriptomics solution such as that offered by expression
array plates processed on the Affymetrix GeneTitan® System – a
platform that is scalable, accurate, and cost-effective,” said
Professor Jamie Timmons, PhD, chief scientific officer at
XRGenomics.
He went on to say “to provide the next generation of clinically
meaningful diagnostics for geriatric medicine, one must
simultaneously assess multiple ‘RNA scores’ or markers for several
age-related chronic diseases to get an accurate picture of the
patient. This is why we are so excited to be working with
Affymetrix to optimize our RNA signatures in thousands of patients
with cognitive impairment using the Affymetrix GeneTitan® platform,
which is extremely well suited to meet the technical demands of
large scale clinical trials.”
“There is a clear need to address the enormous challenge of
managing complex age-related diseases that face healthcare systems
globally. We believe that the work of XRGenomics will materially
improve the research, diagnosis, and treatment of age-related
diseases in the near future,” said Dan St. Louis, senior vice
president of the Expression Business Unit at Affymetrix. “Our
GeneChip® U133 Plus 2.0 array used by XRGenomics, particularly in
its high-throughput automated format, continues to serve as a
proven platform for clinical and translational researchers who need
to analyze the expression profile of large clinical cohorts with
the accuracy, reproducibility, speed, and cost-effectiveness
required to successfully develop complex RNA-based tests for
clinical utility.”
XRGenomics hopes that their biological age signature becomes an
important stratification tool for dementia research as early as
2017.
About XRGenomics LTD
XRGenomics LTD is a privately held company with
informatics-driven research and development activities in the field
of aging and diabetes diagnostics. For more information about
XRGenomics LTD, please visit www.xrgenomics.com
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of benchtop research into
clinical and routine use for human health and wellness. Affymetrix
provides leadership and support, partnering with customers in
pharmaceutical, diagnostic, and biotechnology companies, as well as
leading academic, government, and non-profit research institutes in
their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
94,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, San
Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees
and maintains sales and distribution operations worldwide. For more
information about Affymetrix, please visit www.affymetrix.com
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip,
and GeneTitan trademarks are the property of Affymetrix, Inc. All
other trademarks are the property of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151105005020/en/
Affymetrix Contacts:Media:Mindy Lee-Olsen, 408-731-5523Vice President,
Marketing Servicesmindy_lee-olsen@affymetrix.comInvestors:Doug Farrell, 408-731-5285Vice
President, Investor
Relationsdoug_farrell@affymetrix.comorXRGenomics LTD
Contact:Jamie TimmonsCSOJamie.Timmons@xrgenomics.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024